Polypharmacy and Major Adverse Events in Atrial Fibrillation

Atrial fibrillation is the most common arrhythmia, ranging from 0.1% in patients < 55 years to > 9% in octogenarian patients. Polypharmacotherapy is crucial in atrial fibrillation management, and in many of the concomitant comorbidities, such as hypertension, heart failure, coronary artery disease, and diabetes. However, polypharmacy represents a major concern because of the associated risks of adverse events onset, with an increased risk of all-cause mortality and cardiovascular mortality. In this study, we commented data reported by Tsagkaris et al comparing them with previous reports.